Screener
Aquestive Therapeutics, Inc. AQST Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest expense related to the sale of future revenue | (61) | (61) | (121) | (120) |
| Interest income and other income, net | 882 | 2,096 | 965 | 2,809 |
| Net loss before income taxes | (22,864) | (13,548) | (30,921) | (36,478) |
| Net loss | $(22,864) | $(13,548) | $(30,921) | $(36,478) |
| Comprehensive loss | $(22,864) | $(13,548) | $(30,921) | $(36,478) |
| Loss per share attributable to common stockholders: | ||||
| Basic and diluted (in dollars per share) | $(0.18) | $(0.14) | $(0.25) | $(0.37) |
| Weighted average common shares outstanding: |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s business segments — net loss?
- Aquestive Therapeutics, Inc. (AQST) reported business segments — net loss of -$22.86M in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s business segments — net loss changed year-over-year?
- Aquestive Therapeutics, Inc.'s business segments — net loss decreased by 68.8% year-over-year, from -$13.55M to -$22.86M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s business segments — net loss?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s business segments — net loss has grown at a 226.3% compound annual growth rate (CAGR), from -$7.87M to -$83.78M.
- What does business segments — net loss mean?
- This metric represents the bottom-line financial performance of the company's primary reportable business segment after accounting for all operating costs, research and development expenditures, and administrative overhead. It serves as a critical indicator of the segment's ability to generate sustainable profit relative to its specific cost structure. Investors use this to evaluate the operational viability and burn rate of the company's core pharmaceutical product portfolio.
Ask your AI about Aquestive Therapeutics, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude